Results 51 to 60 of about 5,507 (191)
A Biologically-Based Computational Approach to Drug Repurposing for Anthrax Infection
Toxins, 2017 Developing drugs to treat the toxic effects of lethal toxin (LT) and edema toxin (ET) produced by B. anthracis is of global interest. We utilized a computational approach to score 474 drugs/compounds for their ability to reverse the toxic effects of ...
Jane P. F. Bai +2 more
doaj +1 more source
Drug–drug interaction profile of ritlecitinib as perpetrator and victim through cytochrome P450
British Journal of Clinical Pharmacology, Volume 91, Issue 8, Page 2316-2326, August 2025.Aims To assess the effect of a potent cytochrome P450 (CYP) 3A inhibitor and CYP inducer on the pharmacokinetics of ritlecitinib, a JAK3/TEC family kinase inhibitor, and assess the effect of ritlecitinib on the pharmacokinetics of CYP substrates (midazolam, efavirenz, tolbutamide, caffeine and oral contraceptives [ethinyl oestradiol and levonorgestrel])
Vivek S. Purohit +6 more
wiley +1 more source
The Role of Inflammation in Migraine Headaches: A Review
FASEB BioAdvances, Volume 7, Issue 7, July 2025.Inflammation plays a crucial role in the onset and intensity of both migraine headache symptoms and attacks. Pro‐inflammatory neurotransmitters and mediators released from neural cells and tissues that contributes to increase in nitric oxide, increase in glutamate, alterations in serotonin and dopamine levels and pain perception are involved in ...
Caryn T. Morgan, Sanah M. Nkadimeng
wiley +1 more source
Outpatient treatment of migraine headache, can we use a dexamethasone containing regimen?
Journal of Research in Medical Sciences, 2008 <ul> <li><strong>BACKGROUND</strong>: This research is aimed at determining the efficacy of intravenous dexamethasone and metoclopramide for treatment of acute migraine.
Akbar Hamzeii Moghadam +3 more
doaj
Progress on the development of Class A GPCR‐biased ligands
British Journal of Pharmacology, Volume 182, Issue 14, Page 3249-3300, July 2025.Class A G protein‐coupled receptors (GPCRs) continue to garner interest for their essential roles in cell signalling and their importance as drug targets. Although numerous drugs in the clinic target these receptors, over 60% GPCRs remain unexploited. Moreover, the adverse effects triggered by the available unbiased GPCR modulators, limit their use and
Paula Morales +20 more
wiley +1 more source
Health Expectations, Volume 28, Issue 3, June 2025.ABSTRACT Introduction Long COVID is a complex multisystem illness with multiple relapsing‐remitting symptoms, which can vary in severity and impact people's daily lives. This study utilises the first author's experience of falling ill with and recovering from long COVID to investigate the lived experience of the illness. Learnings that could positively
Sarahjane Belton, Kate Sheridan
wiley +1 more source
RFWD3 Reprograms Nucleotide Metabolism Through PHGDH to Induce Chemoresistance In Osteosarcoma
Advanced Science, Volume 12, Issue 16, April 24, 2025.RFWD3 is identified as a key regulator of cisplatin (DDP) sensitivity in osteosarcoma using a genome‐wide CRISPR screen. RFWD3 promotes PHGDH ubiquitination, enhancing NAD+‐mediated nucleotide biosynthesis. Knocking out RFWD3 sensitized osteosarcoma cells to DDP.
Wenchao Zhang +6 more
wiley +1 more source
Annals of Indian Academy of Neurology, 2002 Pharmacotherapy for migraine involves treatment for the acute attack as well as using long-term prophylaxis in order to reduce the frequency and severity of the attacks. Based on severity, there are a number of drugs available to treat the acute attacks.
Mehndiratta M
doaj
Headache: The Journal of Head and Face Pain, Volume 65, Issue 4, Page 589-607, April 2025.Abstract Objective To estimate rates of migraine progression and assess predictors of progression in a large, longitudinal cohort study using the traditional definition and two alternative definitions of migraine progression. Background Traditionally, migraine progression is defined as moving from episodic migraine (EM) with ≤ 14 monthly headache days (
Dawn C. Buse +8 more
wiley +1 more source
CHIMIA, 2006 The scientific research on ergot alkaloids is fundamentally related to the work of Dr. Albert Hofmann, who was able to produce, from 1935 onwards, a number of novel and valuable drugs, some of which are still in use today.
Rudolf K.A. Giger, Günter Engel
doaj +1 more source